Surgical resection and neoadjuvant therapy in patients with gastric cancer and ovarian metastasis: A real-world study

Table 1 Baseline characteristics of patients in the surgical and non-surgical group

Variables	Surgical group (n = 27)	Non-surgical group (n = 14)	Total (n = 41)	P value
Median age (range)	55.07 ± 11.737	49.50 ± 14.821	53.17 ± 12.963	0.195
Number of metastatic sites	2.00 (1.00-3.00)	2.50 (2.00-3.25)	2.00 (1.00-3.00)	0.301
OM metastases foci size (cm)	6.00 (4.00-12.00)	5.90 (3.40-8.65)	6.00 (4.00-10.50)	0.403
Metastasis of stomach cancer to the ovaries (months)	0.00 (0.00-0.30)	0.00 (0.00-1.32)	0.00 (0.00-2.52)	0.419
Family history of cancer				0.179
Yes, n (%)	4 (14.8)	5 (35.7)	9 (22)
No, n (%)	23 (85.2)	9 (64.3)	32 (78)
ECOG PS 0-1				0.976
Yes, n (%)	25 (92.6)	13 (92.9)	38 (92.7)
No, n (%)	2 (7.4)	1 (7.1)	3 (7.3)
Primary lesion				0.03
Cut, n (%)	15 (55.6)	3 (21.4)	18 (43.9)
Uncut, n (%)	12 (44.4)	11 (78.6)	23 (56.1)
Oligotransfers				0.165
Yes, n (%)	9 (33.3)	2 (14.3)	11 (26.8)
No, n (%)	18 (66.7)	12 (85.7)	30 (73.2)
Ascites				0.149
Yes, n (%)	9 (33.3)	8 (57.1)	17 (41.5)
No, n (%)	18 (66.7)	6 (42.9)	24 (58.5)
Peritoneal metastases				0.428
Yes, n (%)	10 (37)	4 (28.6)	14 (34.1)
No, n (%)	17 (63)	10 (71.4)	27 (65.9)
CA125 > 26.1				0.883
Yes, n (%)	18 (66.7)	9 (64.3)	27 (65.9)
No, n (%)	9 (33.3)	5 (35.7)	14 (34.1)
CA199 > 7.3				0.758
Yes, n (%)	20 (74.1)	11 (78.6)	31 (75.6)
No, n (%)	7 (25.9)	3 (21.4)	10 (24.4)
CEA > 0.95				0.694
Yes, n (%)	24 (88.9)	13 (92.9)	37 (90.2)
No, n (%)	3 (11.1)	1 (7.1)	4 (9.8)
CA125				0.596
Normal, n (%)	14 (51.9)	6 (42.9)	20 (48.8)
Abnormal, n (%)	13 (48.1)	8 (57.1)	21 (51.2)
CA199				0.091
Normal, n (%)	19 (70.4)	6 (42.9)	25 (61)
Abnormal, n (%)	8 (29.6)	8 (57.1)	16 (39)
CEA				0.913
Normal, n (%)	14 (51.9)	7 (50)	21 (51.2)
Abnormal, n (%)	13 (48.1)	7 (50)	20 (48.8)
Bilateral ovarian metastases				0.456
Yes, n (%)	16 (59.3)	10 (71.4)	26 (63.4)
No, n (%)	11 (40.7)	4 (28.6)	15 (36.6)
OM metastases foci size < 3.15				0.604
Yes, n (%)	4 (14.8)	3 (21.4)	7 (17.1)
No, n (%)	23 (85.2)	11 (78.6)	34 (82.9)
OM metastases foci size < 5				0.762
Yes, n (%)	12 (44.4)	5 (35.7)	17 (41.5)
No, n (%)	15 (55.6)	9 (64.3)	24 (58.5)

ECOG PS: Eastern Cooperative Oncology Group Performance Status; CA199: Carbohydrate antigen 199; CEA: Carcinoembryonic antigen; CA125: Carbohydrate antigen 125; OM: Ovarian metastasis.